2.29% -0.035

Sellas Life Sciences Group Inc (SLS)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Sellas Life Sciences Group Inc

(646) 200-5278

7 TIMES SQUARE, NEW YORK, NY

Nächster Verdiensttermin

Neueste SEC-Einreichungen

SLS's Discussions on Twitter

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-07-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-11-01	Eingeleitet	Oppenheimer	Outperform
2018-04-02	Eingeleitet	H.C. Wainwright	Buy
2018-03-19	Hochstufung	Maxim Group	Hold → Buy

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Sellas Life Sciences Group Inc Aktie (SLS) Neueste Nachrichten

How to interpret SELLAS Life Sciences Group Inc (SLS)’s stock chart patterns - US Post News

SELLAS Life Sciences Group (NASDAQ:SLS) Trading Down 3.3% - MarketBeat

SELLAS Life Sciences Group Inc (SLS)’s stock performance: a year in review - US Post News

SELLAS Life Sciences Group Inc (SLS) can make a big difference with a little luck - SETE News

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Drop in Short Interest - MarketBeat

Market Highlights: SELLAS Life Sciences Group Inc (SLS) Ends on a High Note at 1.32 - The Dwinnex

Healthy Upside Potential: SELLAS Life Sciences Group Inc (SLS) - SETE News

Ratios Uncovered: Breaking Down SELLAS Life Sciences Group Inc (SLS)’s Trailing Twelve Months Metrics - The Dwinnex

A closer look at SELLAS Life Sciences Group Inc (SLS)’s stock price trends - US Post News

It makes sense and dollars to buy SELLAS Life Sciences Group Inc (SLS) stock - SETE News

SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results - Defense World

SELLAS Life Sciences Group (NASDAQ:SLS) Posts Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

SLSSELLAS Life Sciences Group, Inc. Latest Stock News & Market Updates - StockTitan

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - The Bakersfield Californian

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Yahoo Finance

SELLAS Life Sciences Group (NASDAQ:SLS) Trading 0.9% Higher - MarketBeat

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Up 0.9% - Defense World

SELLAS gains orphan drug status in EU for PTCL treatment - Investing.com

SELLAS gains orphan drug status in EU for PTCL treatment By Investing.com - Investing.com Canada

Market Recap Check: SELLAS Life Sciences Group Inc (SLS)’s Negative Finish at 1.16, Up/Down -3.33 - The Dwinnex

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - GlobeNewswire

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - StockTitan

Here’s Why SELLAS Life Sciences Group Inc (NASDAQ: SLS) Is A Good Stock To Buy Right Now - Stocks Register

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - Yahoo Finance

This trade activity should not be overlooked: SELLAS Life Sciences Group Inc (SLS) - SETE News

SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow

SELLAS Life Sciences to raise fresh capital via direct offering - Investing.com India

SELLAS Life Sciences to raise fresh capital via direct offering By Investing.com - Investing.com Canada

SELLAS Life Sciences to raise fresh capital via direct offering - Investing.com

SELLAS Life Sciences to raise fresh capital via direct offering By Investing.com - Investing.com Australia

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market - GlobeNewswire

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market - StockTitan

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to ... - WDRB

SLS’s Stock Market Adventure: 36.55% YTD Growth Amidst Volatility - The InvestChronicle

Holdings of SELLAS Life Sciences Group Inc (SLS) are aligned with the stars - SETE News

Investing in SELLAS Life Sciences Group Inc (SLS) might be a great opportunity, but the stock is a bit overvalued - US Post News

Taking on analysts’ expectations and winning: SELLAS Life Sciences Group Inc (SLS) - SETE News

Investors Buy High Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - Defense World

Metric Deep Dive: Understanding SELLAS Life Sciences Group Inc (SLS) Through its Ratios - The Dwinnex

SELLAS gains FDA nod for pediatric leukemia treatment - Investing.com India

SELLAS gains FDA nod for pediatric leukemia treatment - Investing.com

SELLAS Announces U.S. FDA Rare Pediatric Disease - GlobeNewswire

SELLAS Life Sciences Group Inc (SLS) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle

Financial Analysis: SELLAS Life Sciences Group Inc (SLS)’s Ratios Unveil Key Insights - The Dwinnex

What is the investor’s view on SELLAS Life Sciences Group Inc (SLS)? - US Post News

SELLAS Receives European Medicines Agency Orphan Drug - GlobeNewswire

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia - StockTitan

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia - Yahoo Finance

Upward Trajectory: SELLAS Life Sciences Group Inc (SLS) Posts a Gaine, Closing at 1.14 – DWinneX - The Dwinnex

Finanzdaten der Sellas Life Sciences Group Inc-Aktie (SLS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie SLS